Description: BiondVax Pharmaceuticals Ltd., a biopharmaceutical company, develops universal influenza vaccine. Its lead product is the Multimeric-001 universal flu vaccine, which has completed two Phase II and two Phase I/II clinical trials to provide multi-season and multi-strain protection against human influenza virus strains, including seasonal and pandemic flu strains. The company was founded in 2003 and is based in Ness Ziona, Israel.
Home Page: www.biondvax.com
BVXV Technical Analysis
Jerusalem BioPark Building
Jerusalem,
Israel
Phone:
972 8 930 2529
Officers
| Name | Title |
|---|---|
| Mr. Amir Reichman M.B.A., M.Sc. | CEO & Director |
| Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Mr. Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Scientist |
| Mr. Joshua E. Phillipson B.Sc., M.B.A. | Director of Bus. Devel. & Investor Relations |
| Ms. Moran Ahdout Fruchter L.L.B. | Chief of Staff |
| Ms. Dalit Weinstein Fischer | Head of Technical R&D |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.4836 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2015-05-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |